


# Potential EMS Roles in Vaccines and Monoclonal Antibody Infusion



## Logical Partner





The screenshot shows the CDC website's 'Vaccines & Immunizations' section. The main heading is 'COVID-19 Vaccination Provider Support'. Below this is a sub-heading 'Data and Reporting' with a text box stating: 'All COVID-19 vaccination providers must report COVID-19 vaccine inventory daily into VaccineFinder. In some jurisdictions, providers may report vaccine inventory to the jurisdiction's IIS for the jurisdiction to upload into VaccineFinder. If you have questions about the process for your jurisdiction, please contact your jurisdiction's immunization program.' A 'VaccineFinder Info' button is present. Below the text box are two columns of links: 'Enrolling in your jurisdiction/state-based IIS system' and 'Add the COVID-19 vaccine label to your VTrackS profile'. At the bottom of the page are logos for MEDSTAR, NAEMT, ASPR, ECHO, and NREMT.

**Scenario 2** Currently Enrolled in Medicare as Other Provider Type but not Eligible to Bill for Administering Vaccines (e.g. DME Supplier, Ambulance, IDTF, etc.)

**2a** Enroll in Medicare as Mass Immunizer to Roster Bill

The flowchart consists of six steps connected by arrows:

- Enroll as a mass immunizer through the COVID Hotline** (Icon: Syringe)
- Contact the MAC hotline that serves your geographic area** (Icon: Phone)
- Provide the following information including, but not limited to:**
  - Legal business name
  - NPI
  - TIN
  - State license number, if applicable
  - Practice location information
  - Contact information (phone number, email address)
- MAC screens the provider over the phone and establishes temporary Medicare billing privileges. Provider receives notification within 24 hours.** (Icon: Person with lock)
- Submit vaccination claims to Medicare** (Icon: Document with checkmark)

**Electronic Claims:** Contact your Vendor/Clearinghouse or download free PCACE billing software and electronically submit roster claims to your MAC.

**Paper Claims:** Use Health Insurance Claim Form (CMS-1500)

a. Contact your MAC for the roster form

At the bottom of the page are logos for MEDSTAR, NAEMT, ASPR, ECHO, and NREMT.

**FACT SHEET FOR HEALTH CARE PROVIDERS  
EMERGENCY USE AUTHORIZATION (EUA) OF BAMLANIVIMAB**

**AUTHORIZED USE**

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product bamlanivimab for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

**LIMITATIONS OF AUTHORIZED USE**

- Bamlanivimab is not authorized for use in patients:
  - who are hospitalized due to COVID-19, OR
  - who require oxygen therapy due to COVID-19, OR
  - who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.
- Benefit of treatment with bamlanivimab has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.



**CMS.gov**  
Centers for Medicare & Medicaid Services

Search CMS Search

Medicare Medicaid/CHIP Medicare-Medicaid Coordination Private Insurance Innovation Center Regulations & Guidance Research, Statistics, Data & Systems Outreach & Education

Home > Medicare > COVID-19 > \*Updated\* Monoclonal Antibody COVID-19 Infusion

**COVID-19**

- Enrollment for Administering COVID-19 Vaccine Shots
- Coding for COVID-19 Vaccine Shots
- Medicare COVID-19 Vaccine Shot Payment
- Medicare Billing for COVID-19 Vaccine Shot Administration
- SNF- Enforcement Discretion Relating to Certain Pharmacy Billing
- Beneficiary Incentives for COVID-19 Vaccine Shots
- CMS Quality Reporting for COVID-19 Vaccine Shots
- \*Updated\* Monoclonal Antibody COVID-19 Infusion

**Monoclonal Antibody COVID-19 Infusion**

**Table of Contents**

- Medicare Monoclonal Antibody COVID-19 Infusion Program Instruction
- Coding for Monoclonal Antibody COVID-19 Infusion
- Medicare Payment for Monoclonal Antibody COVID-19 Infusion
- Billing for Monoclonal Antibody COVID-19 Infusion Administration

**Medicare Monoclonal Antibody COVID-19 Infusion Program Instruction**

On November 9, 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy, bamlanivimab, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive COVID-19 test results who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab may only be administered in settings in which health care providers have immediate access to medications to treat a severe infusion reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS), as necessary. Review the [Fact Sheet for Health Care Providers EUA of Bamlanivimab](#) regarding the limitations of authorized use.

MEDSTAR NAEMT ASPR ECHO

# Logical Partner

**OUTFRONT**

THANKS FOR KEEPING US SAFE

MEDSTAR NAEMT ASPR ECHO

